- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BIO-WORKS TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 08:09 | BIO-WORKS TECHNOLOGIES AB: Bio-Works reports third quarter 2025 | 1 | Cision News | ||
| Do | BIO-WORKS TECHNOLOGIES AB: Bio-Works receives order for WorkBeads 40S from contract manufacturer in Europe | 3 | Cision News | ||
| 29.10. | BIO-WORKS TECHNOLOGIES AB: Bio-Works forms strategic partnership with Zenmindes Biotechnology to strengthen presence in China | 1 | Cision News | ||
| 21.10. | BIO-WORKS TECHNOLOGIES AB: Bio-Works two largest shareholders, members of the board and the CEO have all exercised all their Warrants TO2 | 1 | Cision News | ||
| 17.10. | BIO-WORKS TECHNOLOGIES AB: Correction: Bio-Works receives order for WorkBeads affimAb valued at approximately SEK 8.3 million | 4 | Cision News | ||
| 17.10. | BIO-WORKS TECHNOLOGIES AB: Bio-Works receives order for WorkBeads affimAb valued at approximately SEK 8.3 million | 1 | Cision News | ||
| 16.10. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB announces outcome from exercise of warrants of series TO 2. Exercise period 4 of 11 | 1 | Cision News | ||
| 08.10. | BIO-WORKS TECHNOLOGIES AB: Strong interest in WorkBeads affimAb Edge: Next-Generation Protein A Resin for Antibody Purification | 3 | Cision News | ||
| 07.10. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies wins appeal against the Swedish Tax Agency in the Supreme Administrative Court | 2 | Cision News | ||
| 01.10. | BIO-WORKS TECHNOLOGIES AB: Today is the first day of the fourth exercise period for Bio-Works Technologies AB's warrants of series TO 2 | 1 | Cision News | ||
| 20.08. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Launches WorkBeads affimAb Edge: Strategic Expansion in the Protein A Resin Market | 1 | Cision News | ||
| 19.08. | BIO-WORKS TECHNOLOGIES AB: Bio-Works two largest shareholders have informed of their intention to exercise all their Warrants TO2 | 1 | Cision News | ||
| 14.08. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB will be publishing the Q2 interim report 2025 tomorrow Friday the 15'th of August | 2 | Cision News | ||
| 15.07. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB announces outcome from exercise of warrants of series TO 2. Exercise period 3 of 11 | 1 | Cision News | ||
| 11.07. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Receives SEK 5.5 Million Order from Global Pharmaceutical Company | 1 | Cision News | ||
| 01.07. | BIO-WORKS TECHNOLOGIES AB: Today is the first day of the third exercise period for Bio-Works Technologies AB's warrants of series TO 2 | 2 | Cision News | ||
| 15.05. | BIO-WORKS TECHNOLOGIES AB: Bio-Works receives WorkBeads order worth SEK 2.5 million | 1 | Cision News | ||
| 15.05. | BIO-WORKS TECHNOLOGIES AB: Resolutions passed at Bio-Works Technologies' annual general meeting 2025 | 16 | Cision News | ||
| 15.05. | BIO-WORKS TECHNOLOGIES AB: Bio-Works reports first quarter 2025 | 1 | Cision News |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HELIX BIOPHARMA | 0,950 | +1,60 % | Helix BioPharma Corp.: Helix BioPharma Announces Presentation at Q3 Investor Summit Virtual on 16 September 2025 | TORONTO, ON / ACCESS Newswire / September 9, 2025 / Helix BioPharma Corp. (TSX:HBP)(OTC:HBPCF)(FRANKFURT:HBP0) ("Helix" or the "Company"), a clinical-stage oncology company shaping a near future where... ► Artikel lesen | |
| GALECTO | 5,710 | 0,00 % | Galecto, Inc.: Galecto Reports Third Quarter 2025 Operating and Financial Results | ||
| JYONG BIOTECH | 38,120 | 0,00 % | Jyong Biotech Ltd.: Jyong Biotech Announces Completion of Patient Enrollment of over 700 subjects in Phase II Clinical Trial of MCS-8 for Prostate Cancer Prevention | New Taipei City, Taiwan, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company", "Jyong Biotech"), a science-driven biotechnology company based in Taiwan committed to... ► Artikel lesen | |
| QIAGEN | 37,355 | -2,26 % | Dax lässt nach - Merck und Qiagen gefragt | Frankfurt/Main - Zum Wochenausklang hat der Dax nachgelassen. Zum Xetra-Handelsschluss wurde der Index mit 23.958 Punkten berechnet, ein Minus in Höhe von 0,7 Prozent im Vergleich zum Vortagesschluss.... ► Artikel lesen | |
| BEAM THERAPEUTICS | 23,150 | 0,00 % | Beam Therapeutics GAAP EPS of -$1.10 misses by $0.09, revenue of $9.69M misses by $3.03M | ||
| DYNE THERAPEUTICS | 18,205 | -12,89 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights | - Topline data from Registrational Expansion Cohort of DELIVER trial of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) in DMD on track for December 2025 to support potential submission... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 69,78 | -0,03 % | Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think) | ||
| NUVALENT | 95,87 | +4,21 % | Nuvalent to present zidesamtinib patient data at lung cancer conference | ||
| EVOTEC | 5,818 | 0,00 % | EQS-News: Evotec SE: In einer wegweisenden Transaktion unterzeichnet Evotec eine Vereinbarung mit Sandoz über potenzielle Zahlungen in Höhe von über 650 Mio. US$ zuzüglich Umsatzbeteiligungen | EQS-News: Evotec SE
/ Schlagwort(e): Vereinbarung
In einer wegweisenden Transaktion unterzeichnet Evotec eine Vereinbarung mit Sandoz über potenzielle Zahlungen in Höhe von über... ► Artikel lesen | |
| ADMA BIOLOGICS | 14,030 | 0,00 % | ADMA's Q3 Earnings Match Estimates, Revenues Beat on Strong Asceniv Sales | ||
| MODERNA | 20,575 | -0,10 % | Moderna: Neues zur Tumor-Therapie mRNA-2808 | Moderna hat den ersten Patient in einer klinischen Phase-1/2-Studie mit dem Wirkstoffkandidaten mRNA-2808 behandelt. Der mRNA-basierte T-Cell-Engager wird nach Angaben des US-Biotechunternehmens vom... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 12,460 | -5,75 % | Amylyx targets avexitide launch in 2027 with recruitment completion for LUCIDITY now expected in Q1 2026 | ||
| RECURSION PHARMACEUTICALS | 4,605 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update | Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells-the second neuro map designed to accelerate treatments for a wide range of neurological... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 25,140 | +3,16 % | Arcutis Biotherapeutics, Inc.: Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology | ZORYVE foam 0.3% was safe, well-tolerated, and demonstrated durable and continuously improving efficacy in the treatment of seborrheic dermatitis up to 52 weeksOnce-daily ZORYVE foam 0.3% is approved... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 3,920 | 0,00 % | Taysha Gene Therapies: Citizens hebt Kursziel auf 8 US-Dollar an |
BIO-WORKS TECHNOLOGIES AB gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,200 Euro und damit -2,91 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIO-WORKS TECHNOLOGIES AB finden Sie auf Wallstreet Online.